Look at what can occur when a disease foundation has a strategy and the research to followup that strategy. Our
fucking failures of stroke associations can't even copy successful non-profits, they are that fucking bad. And our boards of directors don't seem to know how bad they are. Contact me for help.
http://view.michaeljfox-email.org/?qs=3cfc5886715fee08bce2f088292742627c4e1b4424f7dfdf92de61889b7e8fa8237c5377ee82ff38ae5f564c6aca29724d5a65f84923fe64cbb0a22437ef65b57b215c692cd260d4
View this email as a webpage | Add
no-reply@michaeljfox-email.org to your address book |
Contact Us
|
The
Michael J. Fox Foundation (MJFF) works with the Parkinson's community
every day. They tell us they need better treatments to manage symptoms
and side effects -- and most importantly, a cure. Our Foundation is
working urgently to deliver all of these.
We
are energized when we hear of progress toward these goals. Just this
week, an MJFF-funded biotech announced positive Phase I results for a
treatment to help the optimal amount of levodopa (the "gold standard" PD
therapy) reach the right part of the brain with greater precision. The
treatment proved safe and holds potential to help those with advancing
disease maintain a higher quality of life.
And
earlier this fall, a drug that addresses dyskinesia (involuntary
movements often experienced by those taking levodopa long-term) was
submitted for FDA approval, propelled by tools we developed to help rate
patient benefit and recruit clinical trial volunteers. These
advances speak to the unique approach we at the Foundation take to
identifying the most promising ideas in order to yield real scientific
solutions.
It's a strategy that requires efficient problem-solving, smart risk-taking and critically, your support.
We
endeavor only to bring life-changing therapies such as these -- and a
treatment that slows or stops Parkinson's in its tracks -- closer to
patients' hands.
You are a vital part of this work. Please
donate today to help us continue bringing good news to you -- and the
estimated 5 million people living with Parkinson's worldwide.
Todd Sherer, PhD
CEO
P.S. Our commitment to tangible progress for patients is matched with one to use your donations wisely: 89 cents of every dollar we spend goes directly to our programs to speed breakthroughs in PD research.
|
|
|
|
|
No comments:
Post a Comment